Cellular and molecular surrogate markers to monitor targeted and non-targeted antiangiogenic drug activity and determine optimal biologic dose

Yuval Shaked, Guido Bocci, Raquel Munoz, Shan Man, J. M L Ebos, Daniel J. Hicklin, Francesco Bertolini, Robert D'Amato, Robert S. Kerbel

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

Perhaps the most significant recent advance in oncology therapeutics has been the approval of various "molecularly targeted" anti-cancer drugs. Currently, there are a large number of similar drugs in early or late stage development, including antiangiogenic agents. Clinical development of such drugs suffers from several handicaps including determining whether a patient's cancer expresses the target and is functionally contributing to cancer growth, monitoring biologic activity, and determining optimal biologic dose. The last problem is related to the low frequency of objective tumor responses (tumor shrinkage) caused by such drugs, or the lack of dose limiting toxicities necessary to define a maximum tolerated dose (MTD), or expression of optimal therapeutic activity at doses below the MTD, when one can be defined. These problems necessitate the development of alternative pharmacodynamic surrogate markers. Here we summarize several such promising markers for monitoring targeted antiangiogenic activity, and establishing optimal therapeutic/biologic dosing. The first is molecular - plasma VEGF - levels of which are rapidly and significantly increased in a dose dependent manner after injection of normal or tumor bearing mice with anti-VEGFR-2 antibodies. The second is a cellular marker, and more generic in nature - circulating VEGF receptor-2 positive cells found in peripheral blood, some of which may be circulating endothelial progenitor cells. Levels of such cells are suppressed in a dose dependent manner which correlate with previously determined optimal biologic/therapeutic anti-tumor activity of various antiangiogenic drugs or treatments. Finally, another promising marker we discuss is soluble VEGFR-2.

Original languageEnglish
Pages (from-to)551-559
Number of pages9
JournalCurrent Cancer Drug Targets
Volume5
Issue number7
DOIs
Publication statusPublished - Nov 2005

Fingerprint

Biomarkers
Pharmaceutical Preparations
Neoplasms
Vascular Endothelial Growth Factor Receptor-2
Maximum Tolerated Dose
Biological Products
Therapeutics
Vascular Endothelial Growth Factor Receptor
Angiogenesis Inhibitors
Environmental Monitoring
Vascular Endothelial Growth Factor A
Injections
Antibodies
Growth

Keywords

  • Antiangiogenic drugs
  • Circulating endothelial progenitor cells
  • Metronomic chemotherapy
  • Targeted therapies
  • Tumor angiogenesis
  • VEGF

ASJC Scopus subject areas

  • Cancer Research
  • Pharmaceutical Science

Cite this

Cellular and molecular surrogate markers to monitor targeted and non-targeted antiangiogenic drug activity and determine optimal biologic dose. / Shaked, Yuval; Bocci, Guido; Munoz, Raquel; Man, Shan; Ebos, J. M L; Hicklin, Daniel J.; Bertolini, Francesco; D'Amato, Robert; Kerbel, Robert S.

In: Current Cancer Drug Targets, Vol. 5, No. 7, 11.2005, p. 551-559.

Research output: Contribution to journalArticle

Shaked, Yuval ; Bocci, Guido ; Munoz, Raquel ; Man, Shan ; Ebos, J. M L ; Hicklin, Daniel J. ; Bertolini, Francesco ; D'Amato, Robert ; Kerbel, Robert S. / Cellular and molecular surrogate markers to monitor targeted and non-targeted antiangiogenic drug activity and determine optimal biologic dose. In: Current Cancer Drug Targets. 2005 ; Vol. 5, No. 7. pp. 551-559.
@article{f88dcb7c90d04b958eac8f5b970c441f,
title = "Cellular and molecular surrogate markers to monitor targeted and non-targeted antiangiogenic drug activity and determine optimal biologic dose",
abstract = "Perhaps the most significant recent advance in oncology therapeutics has been the approval of various {"}molecularly targeted{"} anti-cancer drugs. Currently, there are a large number of similar drugs in early or late stage development, including antiangiogenic agents. Clinical development of such drugs suffers from several handicaps including determining whether a patient's cancer expresses the target and is functionally contributing to cancer growth, monitoring biologic activity, and determining optimal biologic dose. The last problem is related to the low frequency of objective tumor responses (tumor shrinkage) caused by such drugs, or the lack of dose limiting toxicities necessary to define a maximum tolerated dose (MTD), or expression of optimal therapeutic activity at doses below the MTD, when one can be defined. These problems necessitate the development of alternative pharmacodynamic surrogate markers. Here we summarize several such promising markers for monitoring targeted antiangiogenic activity, and establishing optimal therapeutic/biologic dosing. The first is molecular - plasma VEGF - levels of which are rapidly and significantly increased in a dose dependent manner after injection of normal or tumor bearing mice with anti-VEGFR-2 antibodies. The second is a cellular marker, and more generic in nature - circulating VEGF receptor-2 positive cells found in peripheral blood, some of which may be circulating endothelial progenitor cells. Levels of such cells are suppressed in a dose dependent manner which correlate with previously determined optimal biologic/therapeutic anti-tumor activity of various antiangiogenic drugs or treatments. Finally, another promising marker we discuss is soluble VEGFR-2.",
keywords = "Antiangiogenic drugs, Circulating endothelial progenitor cells, Metronomic chemotherapy, Targeted therapies, Tumor angiogenesis, VEGF",
author = "Yuval Shaked and Guido Bocci and Raquel Munoz and Shan Man and Ebos, {J. M L} and Hicklin, {Daniel J.} and Francesco Bertolini and Robert D'Amato and Kerbel, {Robert S.}",
year = "2005",
month = "11",
doi = "10.2174/156800905774574020",
language = "English",
volume = "5",
pages = "551--559",
journal = "Current Cancer Drug Targets",
issn = "1568-0096",
publisher = "Bentham Science Publishers B.V.",
number = "7",

}

TY - JOUR

T1 - Cellular and molecular surrogate markers to monitor targeted and non-targeted antiangiogenic drug activity and determine optimal biologic dose

AU - Shaked, Yuval

AU - Bocci, Guido

AU - Munoz, Raquel

AU - Man, Shan

AU - Ebos, J. M L

AU - Hicklin, Daniel J.

AU - Bertolini, Francesco

AU - D'Amato, Robert

AU - Kerbel, Robert S.

PY - 2005/11

Y1 - 2005/11

N2 - Perhaps the most significant recent advance in oncology therapeutics has been the approval of various "molecularly targeted" anti-cancer drugs. Currently, there are a large number of similar drugs in early or late stage development, including antiangiogenic agents. Clinical development of such drugs suffers from several handicaps including determining whether a patient's cancer expresses the target and is functionally contributing to cancer growth, monitoring biologic activity, and determining optimal biologic dose. The last problem is related to the low frequency of objective tumor responses (tumor shrinkage) caused by such drugs, or the lack of dose limiting toxicities necessary to define a maximum tolerated dose (MTD), or expression of optimal therapeutic activity at doses below the MTD, when one can be defined. These problems necessitate the development of alternative pharmacodynamic surrogate markers. Here we summarize several such promising markers for monitoring targeted antiangiogenic activity, and establishing optimal therapeutic/biologic dosing. The first is molecular - plasma VEGF - levels of which are rapidly and significantly increased in a dose dependent manner after injection of normal or tumor bearing mice with anti-VEGFR-2 antibodies. The second is a cellular marker, and more generic in nature - circulating VEGF receptor-2 positive cells found in peripheral blood, some of which may be circulating endothelial progenitor cells. Levels of such cells are suppressed in a dose dependent manner which correlate with previously determined optimal biologic/therapeutic anti-tumor activity of various antiangiogenic drugs or treatments. Finally, another promising marker we discuss is soluble VEGFR-2.

AB - Perhaps the most significant recent advance in oncology therapeutics has been the approval of various "molecularly targeted" anti-cancer drugs. Currently, there are a large number of similar drugs in early or late stage development, including antiangiogenic agents. Clinical development of such drugs suffers from several handicaps including determining whether a patient's cancer expresses the target and is functionally contributing to cancer growth, monitoring biologic activity, and determining optimal biologic dose. The last problem is related to the low frequency of objective tumor responses (tumor shrinkage) caused by such drugs, or the lack of dose limiting toxicities necessary to define a maximum tolerated dose (MTD), or expression of optimal therapeutic activity at doses below the MTD, when one can be defined. These problems necessitate the development of alternative pharmacodynamic surrogate markers. Here we summarize several such promising markers for monitoring targeted antiangiogenic activity, and establishing optimal therapeutic/biologic dosing. The first is molecular - plasma VEGF - levels of which are rapidly and significantly increased in a dose dependent manner after injection of normal or tumor bearing mice with anti-VEGFR-2 antibodies. The second is a cellular marker, and more generic in nature - circulating VEGF receptor-2 positive cells found in peripheral blood, some of which may be circulating endothelial progenitor cells. Levels of such cells are suppressed in a dose dependent manner which correlate with previously determined optimal biologic/therapeutic anti-tumor activity of various antiangiogenic drugs or treatments. Finally, another promising marker we discuss is soluble VEGFR-2.

KW - Antiangiogenic drugs

KW - Circulating endothelial progenitor cells

KW - Metronomic chemotherapy

KW - Targeted therapies

KW - Tumor angiogenesis

KW - VEGF

UR - http://www.scopus.com/inward/record.url?scp=27144468094&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27144468094&partnerID=8YFLogxK

U2 - 10.2174/156800905774574020

DO - 10.2174/156800905774574020

M3 - Article

C2 - 16305351

AN - SCOPUS:27144468094

VL - 5

SP - 551

EP - 559

JO - Current Cancer Drug Targets

JF - Current Cancer Drug Targets

SN - 1568-0096

IS - 7

ER -